Compare Heron Therapeutics Inc (HRTX) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs S&P Global Inc — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $63.41M), while S&P Global Inc trades at $409.83 (market cap $121.15B). The key difference: S&P Global Inc is far larger — about 1910.6× Heron Therapeutics Inc's market cap, and S&P Global Inc pays a 0.94% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SPGI | |
|---|---|---|
Market Cap | $63.41M | $121.15B |
Sector | Health | Financials |
52-Week High | $1.49 | $534.79 |
52-Week Low | $0.33 | $370.42 |
Enterprise Value | $161.31M | $132.63B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
S&P Global (SPGI) trades at $408.19, up 0.73% today, with strong analyst support (85.7% buy ratings) and a $523.20 consensus price target suggesting 28% upside. Recent Q2 2026 earnings beat expectations at $4.83 EPS, continuing a trend of profitability with 30.54% net margins. Technical indicators show bearish momentum near key support at $404, while fundamentals reveal robust revenue growth to $15.34B in 2025 and expanding cash flow.
The stock presents a compelling long-term opportunity given its dominant market position in ratings and indices, though near-term technical weakness and competitive pressures pose risks. Earnings consistency and strategic initiatives in AI and data analytics support upside potential, but investors should monitor debt levels increasing to 23.29% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
